• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用促黄体生成激素释放激素类似物治疗前列腺癌后的睾丸组织学。

Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.

作者信息

Johansen T E, Ogreid P, Kjellevold K, Blom P

机构信息

Department of Urology, Akershus Central Hospital, Nordbyhagen, Norway.

出版信息

Br J Urol. 1990 Apr;65(4):376-8. doi: 10.1111/j.1464-410x.1990.tb14759.x.

DOI:10.1111/j.1464-410x.1990.tb14759.x
PMID:2140282
Abstract

Orchiectomy was performed in 16 patients because of progression of prostatic cancer despite adequate medical castration with goserelin (Zoladex, ICI) over a mean period of 17.6 months. Severe tubular atrophy was seen in the testes. The Leydig cells also showed signs of atrophy, a fact that may indicate a direct effect of goserelin on these cells. In 1 patient, however, orchiectomy was postponed for 3 months after cessation of medical castration. The serum testosterone had resumed almost normal values and testicular histology revealed intact spermatogenesis and apparently normal Leydig cells.

摘要

16例患者因前列腺癌进展接受了睾丸切除术,尽管使用戈舍瑞林(诺雷德,帝国化学工业公司)进行了平均17.6个月的充分药物去势治疗。睾丸出现严重的小管萎缩。睾丸间质细胞也显示出萎缩迹象,这可能表明戈舍瑞林对这些细胞有直接作用。然而,1例患者在药物去势停止后,睾丸切除术推迟了3个月。血清睾酮已恢复到几乎正常的值,睾丸组织学显示生精功能完整,睾丸间质细胞明显正常。

相似文献

1
Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.用促黄体生成激素释放激素类似物治疗前列腺癌后的睾丸组织学。
Br J Urol. 1990 Apr;65(4):376-8. doi: 10.1111/j.1464-410x.1990.tb14759.x.
2
U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.英国M1期前列腺癌治疗试验。促黄体生成素释放激素类似物(Zoladex)与睾丸切除术的对比
Am J Clin Oncol. 1988;11 Suppl 2:S169-72. doi: 10.1097/00000421-198801102-00039.
3
[Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].[使用长效促黄体生成素释放激素激动剂进行化学去势作为前列腺癌姑息治疗概念的临床、内分泌及实验研究]
Wien Klin Wochenschr. 1990 Nov 9;102(21):640-7.
4
Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.戈舍瑞林治疗转移性前列腺癌后对睾丸切除术的反应。
Urology. 1991 Jan;37(1):17-21. doi: 10.1016/0090-4295(91)80070-n.
5
Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.每日或每月使用促性腺激素释放激素类似物ICI 118630(诺雷德)的患者与接受睾丸切除术的患者的睾酮和促性腺激素水平概况比较。
Br J Urol. 1986 Oct;58(5):539-44. doi: 10.1111/j.1464-410x.1986.tb05463.x.
6
Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.促性腺激素释放激素激动剂诺雷德长效制剂对大鼠精子发生的保护作用,使其免受细胞毒性药物丙卡巴肼的影响。
Cancer Res. 1990 Feb 1;50(3):568-74.
7
[Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].[促黄体生成素释放激素类似物ICI 118630(诺雷德)缓释(长效)制剂对前列腺癌患者的临床疗效]
Hinyokika Kiyo. 1987 Jan;33(1):141-50.
8
Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.转移性前列腺癌患者中促黄体生成素释放激素类似物(戈舍瑞林)与睾丸切除术的比较。
Br J Urol. 1991 May;67(5):502-8. doi: 10.1111/j.1464-410x.1991.tb15195.x.
9
Pituitary hyperplasia after goserelin (LHRH-analogue) therapy.戈舍瑞林(促性腺激素释放激素类似物)治疗后垂体增生。
Neuropathol Appl Neurobiol. 1991 Feb;17(1):75-81. doi: 10.1111/j.1365-2990.1991.tb00696.x.
10
Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. II. Endocrinology and histology of the testis.前列腺癌患者在使用促性腺激素释放激素激动剂类似物治疗期间的垂体-睾丸功能。II. 睾丸的内分泌学和组织学
J Androl. 1987 Nov-Dec;8(6):363-73. doi: 10.1002/j.1939-4640.1987.tb00978.x.

引用本文的文献

1
Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer.与前列腺癌患者去雄激素治疗后睾酮恢复相关的因素。
Investig Clin Urol. 2018 Jan;59(1):18-24. doi: 10.4111/icu.2018.59.1.18. Epub 2017 Dec 20.
2
Incidental Leydig Cell Tumor in Patient with Hormone Resistant Prostate Cancer.激素抵抗型前列腺癌患者中的偶然性莱迪希细胞瘤
Urol Case Rep. 2017 Apr 19;13:48-50. doi: 10.1016/j.eucr.2017.03.027. eCollection 2017 Jul.
3
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
戈舍瑞林。其药效学和药代动力学特性以及在前列腺癌治疗中的疗效综述。
Drugs Aging. 1995 Apr;6(4):324-43. doi: 10.2165/00002512-199506040-00007.